Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of Fludarabine, Adriamycin and Dexamethasone (FAD) as first line therapy in patients with Peripheral T-cell lymphomas (PTCL). 30 patients will be treated into this study.


Clinical Trial Description

Doxorubicin is often used to treat Peripheral T-cell lymphomas (PTCL). However, patients with PTCL have an especially poor outcome with a 5-year overall survival rate of only 26% following treatment with standard doxorubicin containing regimens. There is general agreement that results with conventional chemotherapy are so poor in patients with most PTCL that new approaches are warranted.The nucleoside analogs are Fludarabine being combined with other agents in PTCL (excluding ALK positive ALCL and primary cutaneous ALCL) is reported by others.We conduct a II stage clinical trials to evaluate the efficacy of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) as first line therapy in patients with in Newly Diagnosed PTCL. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00840385
Study type Interventional
Source Fudan University
Contact Xiaojian Liu, PhD
Phone 8613816983809
Email xiaojian_liu068@hotmail.com
Status Recruiting
Phase Phase 2
Start date November 2007
Completion date November 2010

See also
  Status Clinical Trial Phase
Completed NCT03652727 - FX vs. ECG Guidance for PICC Insertion N/A
Not yet recruiting NCT05856656 - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer N/A
Active, not recruiting NCT02959541 - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Not yet recruiting NCT05927857 - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . Phase 1/Phase 2
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT04466332 - Comparison of Two ECG Guided PICC Insertion Techniques N/A
Not yet recruiting NCT04055038 - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Phase 2/Phase 3
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT04024241 - Medium Dose of Cytarabine and Mitoxantrone
Recruiting NCT06208436 - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Active, not recruiting NCT02304640 - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed NCT02298972 - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer N/A
Terminated NCT01249001 - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents Phase 2
Recruiting NCT03089892 - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy N/A
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Recruiting NCT04472403 - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated NCT02982694 - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Phase 2